Karen L. Houseknecht
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Karen L. Houseknecht has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
Deborah Barlow
University of New England, Biddeford, ME, USA
5 shared publications- Meghan May
Department of Biomedical Sciences, College of Osteopathic Medicine, University of New England, Biddeford, ME 04005, USA
5 shared publications - Daniel J. Brooks
Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
3 shared publications Megan Beauchemin
College of Osteopathic Medicine, University of New England, Biddeford, ME, United States
3 shared publications- Bahman Rostama
Department of Biomedical Sciences University of New England Biddeford Maine USA
2 shared publications - Deborah Barlow
Department of Biomedical Sciences, College of Osteopathic Medicine, University of New England, Biddeford, ME 04005, USA
2 shared publications
Latest Publications
- Open Access
- 15 November 2022
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 16, 1042442
Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world and one of the leading indications for liver transplantation. It is one of the many manifestations of insulin resistance and metabolic syndrome as well as an independent risk factor for cardiovascular disease. There is growing evidence linking the incidence of NAFLD with psychiatric illnesses such as schizophrenia, bipolar disorder and depression mechanistically via genetic, metabolic, inflammatory and environmental factors including smoking and psychiatric medications. Indeed, patients prescribed antipsychotic medications, regardless of diagnosis, have higher incidence of NAFLD than population norms. The mechanistic pharmacology of antipsychotic-associated NAFLD is beginning to emerge. In this review, we aim to discuss the pathophysiology of NAFLD including its risk factors, insulin resistance and systemic inflammation as well as its intersection with psychiatric illnesses.
- 15 November 2022
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 16, 1042442
Open AccessNon-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world and one of the leading indications for liver transplantation. It is one of the many manifestations of insulin resistance and metabolic syndrome as well as an independent risk factor for cardiovascular disease. There is growing evidence linking the incidence of NAFLD with psychiatric illnesses such as schizophrenia, bipolar disorder and depression mechanistically via genetic, metabolic, inflammatory and environmental factors including smoking and psychiatric medications. Indeed, patients prescribed antipsychotic medications, regardless of diagnosis, have higher incidence of NAFLD than population norms. The mechanistic pharmacology of antipsychotic-associated NAFLD is beginning to emerge. In this review, we aim to discuss the pathophysiology of NAFLD including its risk factors, insulin resistance and systemic inflammation as well as its intersection with psychiatric illnesses.
- Open Access
- 24 May 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (6) , 1225
Mechanisms Underlying Antipsychotic-Induced NAFLD and Iron Dysregulation: A Multi-Omic Approach
Atypical antipsychotic (AA) medications are widely prescribed for the treatment of psychiatric disorders, including schizophrenia, bipolar disorder and treatment-resistant depression. AA are associated with myriad metabolic and endocrine side effects, including systemic inflammation, weight gain, dyslipidemia and insulin resistance, all of which are associated with increased incidence of non-alcoholic fatty liver disease (NAFLD). NAFLD is highly prevalent in patients with mental illness, and AA have been shown to increase incidence of NAFLD pre-clinically and clinically. However, the underlying mechanisms have not been described. We mined multi-omic datasets from preclinical murine models of sub-chronic risperidone or olanzapine treatment, in vitro exposure of human cells to risperidone and psychiatric patients following onset of aripiprazole therapy focused on pathways associated with the pathophysiology of NAFLD, including iron accumulation, systemic inflammation and dyslipidemia. We identified numerous differentially expressed traits affecting these pathways conserved across study systems and AA medications. We used these findings to propose mechanisms for AA-associated development of NAFLD and dysregulated iron homeostasis.
- 24 May 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (6) , 1225
Open AccessMechanisms Underlying Antipsychotic-Induced NAFLD and Iron Dysregulation: A Multi-Omic Approach
Atypical antipsychotic (AA) medications are widely prescribed for the treatment of psychiatric disorders, including schizophrenia, bipolar disorder and treatment-resistant depression. AA are associated with myriad metabolic and endocrine side effects, including systemic inflammation, weight gain, dyslipidemia and insulin resistance, all of which are associated with increased incidence of non-alcoholic fatty liver disease (NAFLD). NAFLD is highly prevalent in patients with mental illness, and AA have been shown to increase incidence of NAFLD pre-clinically and clinically. However, the underlying mechanisms have not been described. We mined multi-omic datasets from preclinical murine models of sub-chronic risperidone or olanzapine treatment, in vitro exposure of human cells to risperidone and psychiatric patients following onset of aripiprazole therapy focused on pathways associated with the pathophysiology of NAFLD, including iron accumulation, systemic inflammation and dyslipidemia. We identified numerous differentially expressed traits affecting these pathways conserved across study systems and AA medications. We used these findings to propose mechanisms for AA-associated development of NAFLD and dysregulated iron homeostasis.
- Open Access
- 1 May 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (Supplement) , A239-A240
Sustained Morphine Delivery Suppresses Bone Formation and Alters Metabolic and Circulating miRNA Profiles in Mice
Opioid use is associated with a three to four-fold increase in fracture risk, which is higher in males compared to females. Although one component of that risk may be falls, there is also evidence of altered bone remodeling. However, the mechanisms of these effects are not entirely clear. Our aim was to develop a mouse model of opioid-induced bone loss and study the impact on bone turnover and potential miRNA-mediated regulatory mechanisms. We evaluated the effects of sustained morphine treatment on the skeleton and metabolism of male and female C57BL/6J mice by treating with vehicle (0.9% saline) (n=9–11) or morphine (18 mg/kg) (n=11) using subcutaneous osmotic minipumps for 25 days. Morphine did not influence body weight or food intake, but did reduce fat mass in both sexes. All mice treated with morphine had higher resting energy expenditure and respiratory quotient, indicating a shift toward carbohydrate metabolism. After 25 days of treatment, microComputed Tomography (µCT) analyses indicated that morphine-treated male mice lost 15% of trabecular bone volume fraction (Tb.BV/TV) and 14% of Tb. bone mineral density (BMD) (ppBglap and Dmp1). Circulating miRNA profiles were interrogated in serum collected at day 12 from vehicle- and morphine-treated male and female mice. While very few changes were present in females, there were 14 differentially expressed miRNAs in males treated with morphine that reached a threshold of ≥ 2-fold change and ppp<0.001). Fatty acid metabolism has recently been linked to osteoblast function, and suppression of such pathways is consistent with the finding of increased respiratory quotient. In summary, morphine leads to trabecular bone loss due to reduced bone formation in males. miRNA findings indicate this may be due to altered metabolic control of mineralization. Further investigation into hormonal and metabolic dependency of morphine-induced bone formation changes could lead to clinical mitigation strategies for preventing the adverse effects of opioids on bone health.
- 1 May 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (Supplement) , A239-A240
Open AccessSustained Morphine Delivery Suppresses Bone Formation and Alters Metabolic and Circulating miRNA Profiles in Mice
Opioid use is associated with a three to four-fold increase in fracture risk, which is higher in males compared to females. Although one component of that risk may be falls, there is also evidence of altered bone remodeling. However, the mechanisms of these effects are not entirely clear. Our aim was to develop a mouse model of opioid-induced bone loss and study the impact on bone turnover and potential miRNA-mediated regulatory mechanisms. We evaluated the effects of sustained morphine treatment on the skeleton and metabolism of male and female C57BL/6J mice by treating with vehicle (0.9% saline) (n=9–11) or morphine (18 mg/kg) (n=11) using subcutaneous osmotic minipumps for 25 days. Morphine did not influence body weight or food intake, but did reduce fat mass in both sexes. All mice treated with morphine had higher resting energy expenditure and respiratory quotient, indicating a shift toward carbohydrate metabolism. After 25 days of treatment, microComputed Tomography (µCT) analyses indicated that morphine-treated male mice lost 15% of trabecular bone volume fraction (Tb.BV/TV) and 14% of Tb. bone mineral density (BMD) (ppBglap and Dmp1). Circulating miRNA profiles were interrogated in serum collected at day 12 from vehicle- and morphine-treated male and female mice. While very few changes were present in females, there were 14 differentially expressed miRNAs in males treated with morphine that reached a threshold of ≥ 2-fold change and ppp<0.001). Fatty acid metabolism has recently been linked to osteoblast function, and suppression of such pathways is consistent with the finding of increased respiratory quotient. In summary, morphine leads to trabecular bone loss due to reduced bone formation in males. miRNA findings indicate this may be due to altered metabolic control of mineralization. Further investigation into hormonal and metabolic dependency of morphine-induced bone formation changes could lead to clinical mitigation strategies for preventing the adverse effects of opioids on bone health.
- Open Access
- 8 December 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (24) , 9362
Understanding Mechanisms Underlying Non-Alcoholic Fatty Liver Disease (NAFLD) in Mental Illness: Risperidone and Olanzapine Alter the Hepatic Proteomic Signature in Mice
Patients with severe mental illness have increased mortality, often linked to cardio-metabolic disease. Non-alcoholic fatty liver disease (NAFLD) incidence is higher in patients with schizophrenia and is exacerbated with antipsychotic treatment. NAFLD is associated with obesity and insulin resistance, both of which are induced by several antipsychotic medications. NAFLD is considered an independent risk factor for cardiovascular disease, the leading cause of death for patients with severe mental illness. Although the clinical literature clearly defines increased risk of NAFLD with antipsychotic therapy, the underlying mechanisms are not understood. Given the complexity of the disorder as well as the complex pharmacology associated with atypical antipsychotic (AA) medications, we chose to use a proteomic approach in healthy mice treated with a low dose of risperidone (RIS) or olanzapine (OLAN) for 28 days to determine effects on development of NAFLD and to identify pathways impacted by AA medications, while removing confounding intrinsic effects of mental illness. Both AA drugs caused development of steatosis in comparison with vehicle controls (p < 0.01) and affected multiple pathways relating to energy metabolism, NAFLD, and immune function. AA-associated alteration in autonomic function appears to be a unifying theme in the regulation of hepatic pathology.
- 8 December 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (24) , 9362
Open AccessUnderstanding Mechanisms Underlying Non-Alcoholic Fatty Liver Disease (NAFLD) in Mental Illness: Risperidone and Olanzapine Alter the Hepatic Proteomic Signature in Mice
Patients with severe mental illness have increased mortality, often linked to cardio-metabolic disease. Non-alcoholic fatty liver disease (NAFLD) incidence is higher in patients with schizophrenia and is exacerbated with antipsychotic treatment. NAFLD is associated with obesity and insulin resistance, both of which are induced by several antipsychotic medications. NAFLD is considered an independent risk factor for cardiovascular disease, the leading cause of death for patients with severe mental illness. Although the clinical literature clearly defines increased risk of NAFLD with antipsychotic therapy, the underlying mechanisms are not understood. Given the complexity of the disorder as well as the complex pharmacology associated with atypical antipsychotic (AA) medications, we chose to use a proteomic approach in healthy mice treated with a low dose of risperidone (RIS) or olanzapine (OLAN) for 28 days to determine effects on development of NAFLD and to identify pathways impacted by AA medications, while removing confounding intrinsic effects of mental illness. Both AA drugs caused development of steatosis in comparison with vehicle controls (p < 0.01) and affected multiple pathways relating to energy metabolism, NAFLD, and immune function. AA-associated alteration in autonomic function appears to be a unifying theme in the regulation of hepatic pathology.
- Open Access
- 30 July 2020
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 4 (9)
Association of Beta Blocker Use With Bone Mineral Density in the Framingham Osteoporosis Study: A Cross‐Sectional Study
Some, but not all, prior observational studies have shown that beta blocker (BB) use is associated with lower fracture risk and higher bone mineral density (BMD). Rodent studies show the mechanism to involve the reduction in the effects of beta‐adrenergic signaling on bone remodeling. Because previous studies did not have detailed information on dose, duration, and beta‐1 selectivity, we examined these in a cross‐sectional analysis of the association between BB use and hip and spine BMD using DXA with the Offspring Cohort of the Framingham Heart Study. The sample size was N = 1,520, and 397 individuals used BBs. We used propensity score modeling to balance a comprehensive set of covariates using Inverse Probability of Treatment Weighting (IPTW) to minimize bias due to treatment indication. We found significant differences in BMD between BB users and non‐users for three of four BMD measurements (femoral neck: 3.1%, CI 1.1%, 5.0%; total femur: 2.9%, CI 0.9%, 4.9%; femoral trochanter: 2.4%, CI ‐0.1%, 5.0%; and lumbar spine: 2.7%, CI 0.2%, 5.0%). Results were found to be similar between sexes although the magnitude of association was larger for women. Similar differences were estimated for beta‐1 selective and non‐selective BBs compared with no BB use. We modeled dose in categories (no BB use, low dose, high dose) and as a continuous variable and found an increasing dose response which levels off at higher doses. Finally, associations were similar for short vs. long‐term (≤ 4 years vs. > 4 years) use. In summary, this large comprehensive study shows that BB use is associated with higher BMD in a dose‐related manner regardless of beta‐1 specificity and duration of use, which supports the conduct of a randomized clincial trial of BBs for achieving improvements in BMD for individuals at risk of bone loss with aging.
- 30 July 2020
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 4 (9)
Open AccessAssociation of Beta Blocker Use With Bone Mineral Density in the Framingham Osteoporosis Study: A Cross‐Sectional Study
Some, but not all, prior observational studies have shown that beta blocker (BB) use is associated with lower fracture risk and higher bone mineral density (BMD). Rodent studies show the mechanism to involve the reduction in the effects of beta‐adrenergic signaling on bone remodeling. Because previous studies did not have detailed information on dose, duration, and beta‐1 selectivity, we examined these in a cross‐sectional analysis of the association between BB use and hip and spine BMD using DXA with the Offspring Cohort of the Framingham Heart Study. The sample size was N = 1,520, and 397 individuals used BBs. We used propensity score modeling to balance a comprehensive set of covariates using Inverse Probability of Treatment Weighting (IPTW) to minimize bias due to treatment indication. We found significant differences in BMD between BB users and non‐users for three of four BMD measurements (femoral neck: 3.1%, CI 1.1%, 5.0%; total femur: 2.9%, CI 0.9%, 4.9%; femoral trochanter: 2.4%, CI ‐0.1%, 5.0%; and lumbar spine: 2.7%, CI 0.2%, 5.0%). Results were found to be similar between sexes although the magnitude of association was larger for women. Similar differences were estimated for beta‐1 selective and non‐selective BBs compared with no BB use. We modeled dose in categories (no BB use, low dose, high dose) and as a continuous variable and found an increasing dose response which levels off at higher doses. Finally, associations were similar for short vs. long‐term (≤ 4 years vs. > 4 years) use. In summary, this large comprehensive study shows that BB use is associated with higher BMD in a dose‐related manner regardless of beta‐1 specificity and duration of use, which supports the conduct of a randomized clincial trial of BBs for achieving improvements in BMD for individuals at risk of bone loss with aging.
- Open Access
- 1 July 2020
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 6, 100097
Antipsychotic-induced immune dysfunction: A consideration for COVID-19 risk
- 1 July 2020
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 6, 100097
Open AccessAntipsychotic-induced immune dysfunction: A consideration for COVID-19 risk
- 1 February 2020
- Published by Elsevier in Pharmacological Research
- Vol. 152, 104589
Exploring mechanisms of increased cardiovascular disease risk with antipsychotic medications: Risperidone alters the cardiac proteomic signature in mice
- 1 February 2020
- Published by Elsevier in Pharmacological Research
- Vol. 152, 104589
Exploring mechanisms of increased cardiovascular disease risk with antipsychotic medications: Risperidone alters the cardiac proteomic signature in mice
- Open Access
Propranolol promotes bone formation and limits resorption through novel mechanisms during anabolic parathyroid hormone treatment in female C57BL/6J mice
Although the non-selective β-blocker, propranolol, improves bone density with PTH treatment in mice, the mechanism of this effect is unclear. To address this, we used a combination of in vitro and in vivo approaches to address how propranolol influences bone remodeling in the context of PTH treatment. In female C57BL/6J mice, intermittent PTH and propranolol had complementary effects in the trabecular bone of the distal femur and L5 vertebra, with combination treatment achieving micro-architectural parameters beyond that of PTH alone. Combined treatment improved the serum bone formation marker, P1NP, but did not impact other histomorphometric parameters relating to osteoblast function at the L5. In vitro , propranolol amplified the acute, PTH-induced, intracellular calcium signal in osteoblast-like cells. The most striking finding, however, was suppression of PTH-induced bone resorption. Despite this, PTH-induced receptor activator of nuclear factor kappa-B ligand (RANKL) mRNA and protein levels were unaltered by propranolol, which led us to hypothesize that propranolol could act directly on osteoclasts. Using in situ methods, we found Adrb2 expression in osteoclasts in vivo , suggesting β-blockers may directly impact osteoclasts. Taken together, this work suggests a strong anti-osteoclastic effect of non-selective β-blockers in vivo , indicating that combining propranolol with PTH could be beneficial to patients with extremely low bone density.
Open AccessPropranolol promotes bone formation and limits resorption through novel mechanisms during anabolic parathyroid hormone treatment in female C57BL/6J mice
Although the non-selective β-blocker, propranolol, improves bone density with PTH treatment in mice, the mechanism of this effect is unclear. To address this, we used a combination of in vitro and in vivo approaches to address how propranolol influences bone remodeling in the context of PTH treatment. In female C57BL/6J mice, intermittent PTH and propranolol had complementary effects in the trabecular bone of the distal femur and L5 vertebra, with combination treatment achieving micro-architectural parameters beyond that of PTH alone. Combined treatment improved the serum bone formation marker, P1NP, but did not impact other histomorphometric parameters relating to osteoblast function at the L5. In vitro , propranolol amplified the acute, PTH-induced, intracellular calcium signal in osteoblast-like cells. The most striking finding, however, was suppression of PTH-induced bone resorption. Despite this, PTH-induced receptor activator of nuclear factor kappa-B ligand (RANKL) mRNA and protein levels were unaltered by propranolol, which led us to hypothesize that propranolol could act directly on osteoclasts. Using in situ methods, we found Adrb2 expression in osteoclasts in vivo , suggesting β-blockers may directly impact osteoclasts. Taken together, this work suggests a strong anti-osteoclastic effect of non-selective β-blockers in vivo , indicating that combining propranolol with PTH could be beneficial to patients with extremely low bone density.
- Open Access
- 23 October 2019
- Published by Springer Nature in BMC Veterinary Research
- Vol. 15 (1) , 1-6
Polymicrobial abscess following ovariectomy in a mouse
Background Ovariectomy is a common procedure in laboratory rodents used to create a post-menopausal state. Complications including post-surgical abscess are rarely reported, but merit consideration for the health and safety of experimental animals. Case presentation A female C57/black6 mouse was ovariectomized as part of a cohort study. At Day 14 post-surgery, she developed a visible swelling on the right side, which 7 days later increased in size over 24 h, leading to euthanasia of the animal. Gross pathology was consistent with abscess. A core of necrotic tissue was present in the uterine horn. Abscess fluid and affected tissue were collected for Gram stain and bacteriological culture. The abscess core and fluid yielded three distinct types of bacterial colonies identified by 16S ribosomal RNA sequencing as Streptococcus acidominimus, Pasteurella caecimuris, and a novel species in the genus Gemella. Conclusions This is the first report of polymicrobial abscess in a rodent as a complication of ovariectomy, and the first description of a novel Gemella species for which we have proposed the epithet Gemella muriseptica. This presentation represents a potential complication of ovariectomy in laboratory animals.
- 23 October 2019
- Published by Springer Nature in BMC Veterinary Research
- Vol. 15 (1) , 1-6
Open AccessPolymicrobial abscess following ovariectomy in a mouse
Background Ovariectomy is a common procedure in laboratory rodents used to create a post-menopausal state. Complications including post-surgical abscess are rarely reported, but merit consideration for the health and safety of experimental animals. Case presentation A female C57/black6 mouse was ovariectomized as part of a cohort study. At Day 14 post-surgery, she developed a visible swelling on the right side, which 7 days later increased in size over 24 h, leading to euthanasia of the animal. Gross pathology was consistent with abscess. A core of necrotic tissue was present in the uterine horn. Abscess fluid and affected tissue were collected for Gram stain and bacteriological culture. The abscess core and fluid yielded three distinct types of bacterial colonies identified by 16S ribosomal RNA sequencing as Streptococcus acidominimus, Pasteurella caecimuris, and a novel species in the genus Gemella. Conclusions This is the first report of polymicrobial abscess in a rodent as a complication of ovariectomy, and the first description of a novel Gemella species for which we have proposed the epithet Gemella muriseptica. This presentation represents a potential complication of ovariectomy in laboratory animals.